Statins-mediated inhibition of rho GTPases as a potential tool in anti-tumor therapy

Mini Rev Med Chem. 2008 Jun;8(6):609-18. doi: 10.2174/138955708784534436.

Abstract

Rho GTPases, which control processes such as cell proliferation and cytoskeleton remodeling, are often hyper-expressed in tumors. Several members, such as RhoA/B/C, must be isoprenylated to interact with their effectors. Statins, by inhibiting the synthesis of prenyl groups, may affect RhoA/B/C activity and represent a promising tool in anticancer therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Models, Biological
  • Prenylation
  • rho GTP-Binding Proteins / antagonists & inhibitors*
  • rho GTP-Binding Proteins / metabolism

Substances

  • Antineoplastic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • rho GTP-Binding Proteins